MWA
CTSO icon

Medallion Wealth Advisors’s Cytosorbents Corp CTSO Stock Holding History

Medallion Wealth Advisors’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45
Closed -$29 – 1129
2025
Q4 		$29 Hold
45
– – ﹤0.01% 1110
2025
Q3 		$42 Hold
45
– – ﹤0.01% 1094
2025
Q2 		$58 Hold
45
– – ﹤0.01% 1083
2025
Q1 		$45 Hold
45
– – ﹤0.01% 1060
2024
Q4 		$41 Buy
+45
New +$44 ﹤0.01% 1005

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Medallion Wealth Advisors's CTSO Position: Q1 2026 in Review

Medallion Wealth Advisors sold out of Cytosorbents Corp (CTSO) in Q1 2026, closing a stake of 45 shares — an estimated $29 sold.

Medallion Wealth Advisors first reported a position in CTSO in Q4 2024 and held it in 5 quarters. The position peaked at $58 in Q2 2025. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Medallion Wealth Advisors reported no remaining Cytosorbents Corp position as of Q1 2026 after selling out during the quarter.
  • Medallion Wealth Advisors sold 45 Cytosorbents Corp shares in Q1 2026, an estimated $29.
  • Medallion Wealth Advisors first reported a position in Cytosorbents Corp in Q4 2024 and held it in 5 quarters.
  • Medallion Wealth Advisors's Cytosorbents Corp position peaked at $58 in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.